Ivergalen (Ivermectin)

Ivermectin binds to glutamate‑gated chloride channels in the nervous system of parasites, causing an influx of chloride ions. This hyperpolarizes the cells, leading to paralysis and death of the parasite, while having limited activity on human cells at therapeutic doses.

The exact dose of Ivergalen is determined by the prescribing clinician based on the specific indication, patient weight, age and clinical condition. Healthcare professionals follow approved guidelines and adjust the regimen as needed for each individual case.

Safety data for ivermectin in pregnancy and lactation are limited. It should be used only if the potential benefit justifies the possible risk to the fetus or infant, and the decision must be made by a qualified healthcare provider.

To place an order, submit an enquiry on the Ivergalen product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Ivergalen (ivermectin) belongs to the macrocyclic lactone class and offers a broad spectrum against several parasites. Compared with older agents like albendazole, ivermectin often requires fewer doses and has a distinct mechanism targeting chloride channels, making it a preferred option for the listed indications.

Ivergalen should be stored at ambient temperature, below 25 °C, in its original packaging. Keep the product away from moisture, direct sunlight and excessive heat to maintain its potency throughout its shelf life.

Ivergalen is taken orally, usually as a tablet, with or without food as directed by the prescriber. The exact administration schedule depends on the condition being treated and the dose prescribed by the healthcare professional.

Serious adverse events, though rare, can include severe skin reactions such as Stevens‑Johnson syndrome, hepatotoxicity, neurologic toxicity (e.g., seizures), marked hypotension and anaphylaxis. Patients should seek immediate medical attention if they experience any of these symptoms.

Ivergalen is contraindicated in individuals with known hypersensitivity to ivermectin or any component of the formulation. Caution is advised for patients with significant liver disease, pregnant women, and those taking strong CYP3A4 or P‑gp inhibitors unless the prescriber determines that benefits outweigh risks.